Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its achievement of surpassing a significant milestone of 500 peer-reviewed publications featuring its technology in esteemed scientific journals. This milestone highlights Guardant Health’s leadership, amassing one of the most robust portfolios of relevant liquid biopsy research studies in the industry.

These publications have profoundly impacted the oncology field, including validating Companion Diagnostic (CDx) claims, driving changes in the National Comprehensive Cancer Network (NCCN) guidelines for liquid biopsy, and providing essential clinical outcomes data. This includes publications across multiple cancers, including 189 in lung cancer, 53 in breast cancer, and 51 in colorectal cancer, continuing the company’s approach of starting with lung cancer and expanding its product portfolio into other diseases.

“We have partnered with thousands of authors representing diverse perspectives and expertise worldwide,” said Dr. Craig Eagle, chief medical officer at Guardant Health. “We accelerated our publication rate over the past two years, averaging approximately 100 publications annually, with some of the brightest minds in the scientific community.”

Publications include notable collaborations with 45 National Cancer Institute (NCI)-Designated Cancer Centers, underlining the trust and confidence of Guardant Health in cancer research.

“High-quality science has always been the driving force in our mission to conquer cancer with data,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “We are proud to have collaborated with leading scientists over the past 12 years to conduct some of the largest and most impactful studies ever to be performed in our field. This incredible breadth of clinical data demonstrates the real-world impact of our technology on patient outcomes, advances the clinical utility and value of our tests, and helps to improve payer coverage and patient access.”

About Guardant Health

Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507852378/en/